SEATTLE & VANCOUVER, British Columbia–Pascal Biosciences Inc. (TSX.V:PAS) (OTC:BIMUF) (“Pascal” or the “Company”) and SōRSE Technology Corporation (“SōRSE”) have validated and optimized a formula for oral cannabinoid delivery. Their shared efforts are advancing the cannabinoid PAS-393 towards clinical testing against cancer.
“This progress is very promising because this step is critical for testing in human volunteers,” said Pascal CEO Patrick Gray. “We will next identify a drug product manufacturer to prepare our product for testing in cancer patients treated with checkpoint inhibitors.”
It will be the first pharmaceutical use of the novel formulation technology developed by SōRSE and the first clinical trial for Pascal and SōRSE. This collaboration utilizes propriety discoveries by both companies, including Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors, and SōRSE’s proprietary formulation expertise.
“It’s great to see such rapid progress with the in vitro studies using our formulation technology,” said SōRSE CEO Howard Lee. “We are on track to enter our first clinical trial with Pascal within a year.”
Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SōRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor.
About Pascal Biosciences Inc.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal’s leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. For more information, visit www.pascalbiosciences.com.
About SōRSE Technology
SōRSE Technology Corporation is a water-soluble emulsion technology designed for product developers to provide consumers with a better, more consistent cannabinoid experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Its patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for infusing CBD and other functional ingredients into beverages, food items, topicals, and medical applications. SōRSE Technology currently powers more than 45 leading products in the CBD space. For more information, visit www.sorsetechnology.com.
SōRSE Technology Press:
Jon Lindsay Phillips